A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
You can google it and from the results it appears that they are attempting to get the correct dosage. This would be a positive indicator right?
Japanese subjects. So this would be the first step towards an approval in Japan (with rest of Asia likely to follow along).
That per see is not worth a hell of a lot, but it is of course a plus that Merck see the value in spending money on more trials.